Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial
Journal article
Marcovecchio ML. et al, (2020), Wellcome Open Research, 5, 49 - 49
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
Journal article
Urbonas V. et al, (2019), Annals of Oncology, 30, 317 - 324
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Journal article
Iveson TJ. et al, (2018), The Lancet Oncology, 19, 562 - 578
Abstract CT123: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in advanced wild type BRAF melanoma
Conference paper
Middleton MR. et al, (2017), Clinical Trials
Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer.
Conference paper
Iveson T. et al, (2017), JOURNAL OF CLINICAL ONCOLOGY, 35
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Journal article
Kerr RS. et al, (2016), The Lancet Oncology, 17, 1543 - 1557
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS
Journal article
Rosmarin D. et al, (2015), Gut, 64, 111 - 120
Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis
Journal article
Rosmarin D. et al, (2014), Journal of Clinical Oncology, 32, 1031 - 1039